Last updated: June 13, 2026
VISIPAQUE 320 market dynamics and financial trajectory (Iohexol 64% w/v, 320 mgI/mL)
VISIPAQUE 320 (iohexol injection, 320 mgI/mL) is an established radiographic iodinated contrast medium (ICM) used for CT and angiography-like contrast imaging. The market is shaped by (1) patent and exclusivity saturation in most major geographies, (2) recurring procurement and tender dynamics across hospitals and GPOs, (3) supply resilience and manufacturing leverage among a small set of global ICM suppliers, and (4) clinical and pharmacovigilance-driven switching around product-specific tolerability profiles and imaging protocols. Financial trajectory is typically flat-to-maturing in developed markets with growth driven by procedure volumes, utilization expansion in CT, and periodic unit-price pressure offsets. In practice, VISIPAQUE 320’s trajectory tracks global ICM pricing, tender wins, and mix shifts (CT share, volume-per-scan intensity) more than incremental innovation.
Core economic drivers
- Procedure volume growth: CT utilization expansion increases iodinated contrast demand per patient.
- Price compression: ICM procurement frequently benchmarks to multiple generic/“authorized” competitors, pushing down net price.
- Mix shift: Higher scan complexity and angiography use can increase dosing per exam, partially offsetting price declines.
- Product access and formulary position: Hospital contracts and pharmacy formularies are decisive for unit volume.
- Supply and regulatory continuity: ICM markets penalize supply interruptions; qualified alternative sourcing can shift volume quickly.
Snapshot: what “VISIPAQUE 320” competes against
VISIPAQUE 320’s economic perimeter sits within the broader iodinated contrast competitive set, including:
- Other iohexol presentations from multiple manufacturers and authorized sources.
- Alternative ICM chemistries (e.g., iopamidol, ioversol, iodixanol) where imaging protocols permit interchangeability.
- Private-label and tender-optimized SKUs used by hospital groups.
This positioning drives the typical financial pattern for legacy ICMs: volume resilience with recurring net price erosion.
How big is the iodinated contrast media market and where does VISIPAQUE 320 fit?
Featured snippet answer: VISIPAQUE 320 is a segment within the global iodinated contrast media (ICM) market; the ICM market is dominated by CT-driven demand, with additional angiography and interventional procedures contributing.
Demand mix that typically supports revenue stability
- CT imaging is the principal use case for iodinated ICMs in developed markets.
- Interventional radiology and vascular imaging add higher dosing variability, supporting mix-driven growth in some periods.
- Emergency and chronic disease imaging tends to create baseline demand, lowering volatility.
How VISIPAQUE 320 fit affects pricing power
VISIPAQUE 320 is not usually a “price-leader by innovation,” so it generally competes on:
- Contract placement (GPO, IDN tender awards)
- Supply reliability
- Dosing convenience and SKU fit
- Clinical protocol adoption and radiology department preference
What are the key market dynamics for VISIPAQUE 320 (CT volume, tenders, and substitution)?
Featured snippet answer: VISIPAQUE 320 faces a recurring cycle of CT utilization growth offset by tender-based unit price pressure and substitution among iodinated contrast products.
1) Tender and contracting dynamics in hospital ICM purchasing
ICM is typically purchased through:
- GPO national contracts
- Regional IDN tenders
- Hospital pharmacy-managed formularies
- Radiology service-line protocol standardization
Once a product becomes the “default” in a protocol, switching costs fall. That shifts growth from brand marketing to procurement execution.
2) Substitution among iodinated contrast agents
Substitution is driven by:
- Clinical equivalence perceptions across nonionic, low-osmolality agents (class effect)
- Dose and viscosity fit for scan requirements and injection systems
- Site-specific experience
- Availability
Because many ICMs are therapeutically substitutable within imaging workflows, price competition can be intense during renewals.
3) Supply chain and manufacturing constraints
ICM is sensitive to:
- Raw iodinated intermediates supply
- Sterile manufacturing capacity
- Quality system continuity
- Regulatory inspection outcomes
Supplies that fail quality or availability tests can lose volume quickly to alternate SKUs, even if it later regains distribution.
When does VISIPAQUE 320 face exclusivity expiry and what does that mean for revenue?
Featured snippet answer: VISIPAQUE 320 is a mature, legacy iodinated contrast product, so most major exclusivity-based revenue shields are already exhausted or limited by incremental formulation-level rights rather than core active ingredient dominance.
Practical impact of “mature product” dynamics
- Net revenue tends to track contracts and procedure volume rather than protected price premiums.
- Generic/authorized alternatives typically cap sustainable price increases and intensify unit volume competition.
- Brand differentiation often shifts to service agreements (supply assurance, forecasting support) rather than exclusivity.
Common financial consequence
- Gross-to-net compression rises around contract renewals and pricing resets.
- Market share volatility increases during tender cycles.
What patent and litigation risks exist for VISIPAQUE 320 market access?
Featured snippet answer: In mature ICM categories like iohexol, market access risks are generally tied to generic/authorized entrant timing and any remaining formulation or manufacturing-process patents, rather than broad end-of-exclusivity barriers.
How patent estate usually maps to business outcomes
- If core rights are expired, entry is mainly regulated by:
- ANDA/authorization pathways (depending on jurisdiction)
- CMC and device compatibility (where applicable)
- Labeling and dosing conformity
- Residual risks tend to be:
- Late-stage formulation patents
- Manufacturing method patents
- Method-of-use claims (less common for contrast media but possible)
Revenue exposure channel
Even without explicit litigation, “paper access” timelines matter:
- If an entrant can launch quickly, incumbent unit volumes can drop in renewal cycles.
- If injunctions or settlements delay entry, price pressure can remain below full competitive intensity.
What is the Orange Book status of VISIPAQUE 320 and how does it affect generics?
Featured snippet answer: VISIPAQUE 320’s Orange Book status depends on the specific FDA NDA listing and listed patents for the ibox/strength and presentation. The resulting status determines whether generic competitors must clear patent hurdles or wait out listed expirations.
How Orange Book listing changes pricing
- Listed patents at launch time increase barriers to generic entry and protect market share longer.
- De-listing or expiration reduces barriers and accelerates substitution in formularies.
Business relevance
For mature ICMs, the Orange Book status mainly affects:
- Timing of authorized/generic procurement bids
- Hospital confidence in future supply options
- Incumbent ability to defend contract renewals
How does VISIPAQUE 320 compare with other iodinated contrast agents on commercial trajectory?
Featured snippet answer: VISIPAQUE 320 competes primarily on contract wins rather than sustained premium pricing versus other iohexol and non-iohexol ICMs.
Competitive comparison angles that drive share
- Unit price and pack configuration (vials vs larger packs and dosing fit)
- Viscosity, injection capability, and protocol fit
- Radiology department historical preference
- Pharmacovigilance experience and adverse event reporting outcomes
- Supply continuity
Typical outcome in developed markets
- Agents with stable supply and favorable net pricing gain traction.
- Brand-led differentiation is limited once multiple comparable alternatives are formulary-available.
Which companies supply competitive iodinated contrast products that pressure VISIPAQUE 320 pricing?
Featured snippet answer: The ICM space is dominated by a small set of global manufacturers and authorized competitors; pricing pressure typically comes from multiple parallel product sources at comparable clinical performance.
What to watch for in competitor behavior
- Aggressive tender pricing close to contract renewal windows
- Bundle offers (multiple strengths or related contrast SKUs)
- Supply guarantees that win institutional switching decisions
- Rapid launch capability after removals of patent/market access barriers
What formulations, strengths, and packaging drive VISIPAQUE 320 volume and net price?
Featured snippet answer: VISIPAQUE 320 volume and net price depend on the specific presentation used in each hospital protocol, including pack size and injection workflow compatibility.
Commercial sensitivity to dosing fit
Contrast spend often varies because:
- Institutions standardize on a limited set of strengths to simplify workflow.
- CT protocols may use defined dosing ranges by patient class, affecting SKU usage proportions.
How do FDA labeling and clinical protocol changes affect VISIPAQUE 320 demand?
Featured snippet answer: Demand is influenced by label positioning and by radiology protocol adoption; changes that expand or restrict eligible use cases can shift volume between ICM SKUs and competing agents.
Where label matters in procurement
- Eligibility wording for specific imaging types
- Contraindication clarifications
- Warnings that affect site risk management decisions
- Compatibility with injection equipment and procedures
What generic entry risks exist for VISIPAQUE 320, and how do they show up in financial results?
Featured snippet answer: Generic entry risks manifest as downward unit price trends, share loss during tender renewals, and higher gross-to-net.
Risk channels
- Authorized generic or generic launch: immediate procurement price benchmarking
- Substitution within class: shifting volume to alternative ICM chemistries
- Formulary changes: protocol changes can accelerate switching
Financial indicators that usually confirm risk
- Net sales declines not fully explained by procedure volumes
- Increased trade spending and rebates
- Margin compression from contract concessions
What revenue trajectory pattern should investors and licensors expect for mature ICM brands like VISIPAQUE 320?
Featured snippet answer: Mature ICM products typically show mid-single-digit or low-growth unit volume trends in developed markets with recurring price compression, producing flat-to-moderate net revenue growth.
Typical pattern by lifecycle stage
- Post-launch / early growth: share building, higher net price.
- Maturity: stabilized volume with contracting-driven price compression.
- Late maturity: increased substitution risk, more volatile share, margin pressure.
Net sales is driven by
- CT exam growth
- Contract renewals
- Mix changes
- Supply stability
Key financial drivers table: what moves VISIPAQUE 320 net sales most
| Driver |
Direction |
Why it matters commercially |
| CT procedure volume growth |
Up |
Expands addressable contrast demand |
| Hospital tender pricing |
Down |
Net price compression and share switching |
| Mix (higher dose protocols) |
Up |
More mL or higher strength usage per exam |
| Supply continuity |
Up/Down |
Stockouts shift volume to competitors |
| Formulary/protocol adoption |
Up/Down |
Determines “default” ordering behavior |
| Competitor entry timing |
Down |
Accelerates benchmarking and substitution |
| Trade/rebate intensity |
Down margin |
Increases gross-to-net pressure during competition |
Key takeaways
- VISIPAQUE 320’s market dynamics follow the iodinated contrast pattern: CT-driven demand with procurement-led pricing pressure and strong substitution among comparable ICMs.
- Financial trajectory is typically mature-product behavior: volume resilience with recurring net price compression tied to tender cycles, supply stability, and formulary placement.
- Revenue downside risk is most likely to appear at contract renewals when alternative iohexol and competing ICM chemistries are priced aggressively and can support equivalent imaging workflows.
FAQs
1) How does CT volume growth translate into iodinated contrast spending for VISIPAQUE 320
CT utilization growth increases the number of contrast-exposed scans and often increases total mL consumption per patient protocol, supporting incremental unit demand.
2) Why do iodinated contrast products lose pricing power even after strong clinical adoption
Because procurement policies benchmark across multiple therapeutically substitutable ICMs, long-term pricing is reset through tenders rather than protected by clinical preference alone.
3) What contract features most strongly affect VISIPAQUE 320 net price
GPO and IDN tender terms, rebate structures, price caps, volume commitments, and supply assurance clauses.
4) Do supply disruptions have a lasting effect on VISIPAQUE 320 share
Yes. Once hospitals qualify alternate SKUs during shortages, switching often persists through subsequent tenders even after supply normalizes.
5) How do alternative ICM chemistries pressure VISIPAQUE 320 in formularies
If institutions allow multiple nonionic low-osmolality agents in the same protocol class, competing chemistries can be substituted based on net price and availability.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drug Approval Package for VISIPAQUE (iohexol) and related NDA listings. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Guidance for Industry: Patient Labeling and Medication Guides for Human Prescription Drug Products (general regulatory context affecting labels and adoption). U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents
- Society for Imaging Informatics in Medicine (SIIM) and radiology practice resources (CT contrast utilization context). https://www.siim.org/
